North East and North Cumbria
ICS Formulary
ICS Formulary
10 Musculoskeletal and joint diseases
10-01-03 Sulfasalazine
| Sulfasalazine E/C tablets |
|
Formulary
|
 NENC Shared Care Protocol - Sulfasalazine for patients within adult services |
|
Links
Clinical Commissioning Policy (210505P) Statement: Abatacept for treatment of severe treatment-resistant morphoea (localised scleroderma)- Clinical Commissioning Policy Baricitinib for use in monogenic interferonopathies (adults and children 2 years and over) (210506P)
- Clinical Commissioning Policy: Baricitinib for patients hospitalised due to COVID-19 (adults and children aged 2 years and over)
- County Durham and Darlington Shared Care Guideline: Ciclosporin
- County Durham and Darlington Shared Care Guideline: Methotrexate
- Durham and Darlington Shared Care Guidance
- Guidelines for the Management of Adults with Asymptomatic Liver Blood Test Abnormalities
- MHRA Drug Safety Update - June 2019 - Myocrisin permanent discontinuation
- MHRA Drug Safety Update (April 2014): Tumour necrosis factor alpha inhibitors: risk of tuberculosis - screen all patients before starting treatment and monitor them closely
- MHRA Drug Safety Update (April 2019): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (April 2023): Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA Drug Safety Update (Aug 2020): Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
- MHRA Drug Safety Update (August 2023): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions
- MHRA Drug Safety Update (Dec 2013): Rituximab: screen for hepatitis B virus before treatment.
- MHRA Drug Safety Update (Dec 2014): Rituximab: progressive multifocal leukoencephalopathy in a patient
- MHRA Drug Safety Update (Feb 2022): Hydroxychloroquine, chloroquine: increased risk of cardiovascular events when used with macrolide antibiotics; reminder of psychiatric reactions
- MHRA Drug Safety Update (Jan 2015): Ustekinumab (Stelara): risk of exfoliative dermatitis
- MHRA Drug Safety Update (Jan 2017): Apremilast (Otezla ▼): risk of suicidal thoughts and behaviour
- MHRA Drug Safety Update (July 2019): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- MHRA Drug Safety Update (Mar 2020): Baricitinib (Olumiant▼): risk of venous thromboembolism
- MHRA Drug Safety Update (Mar 2020): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections
- MHRA Drug Safety Update (May 2019): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of pulmonary embolism while safety review is ongoing
- NENC Shared Care Protocol - Azathioprine and mercaptopurine within adult services (non-transplant indications)
- NENC Shared Care Protocol - Hydroxychloroquine for patients within adult services
- NENC Shared Care Protocol - Leflunomide for patients within adult services
- NENC Shared Care Protocol - Mycophenolate mofetil and mycophenolic acid in adults (non-transplant indications)
- NENC Shared Care Protocol - Sulfasalazine for patients within adult services
- Newcastle, North Tyneside, Northumberland & Gateshead - Guidelines for Monitoring of Immune Modifying Drugs (IMDs) in Stable Adult Patients (excluding post transplantation) in Primary and Secondary Care
- NHS England Commissioning Policies (Specialised Rheumatology)
- NHSE Specialised Commissioning Policy: Infliximab for refractory sarcoidosis (excluding neurosarcoidosis) (adults)
- NICE NG100: Rheumatoid arthritis in adults: management
- NICE NG226: Osteoarthritis in over 16s: diagnosis and management
- NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
- NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
- NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
- NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
- NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
- NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA199: Psoriatic arthritis
- NICE TA220: psoriatic arthritis
- NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
- NICE TA340: Ustekinumab for treating active psoriatic arthritis (Updated March 2017)
- NICE TA35: Adult psoriasis
- NICE TA35: Adult psoriasis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
- NICE TA433: Apremilast for treating active psoriatic arthritis
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
- NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance
- NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
- NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
- NICE TA518: Tocilizumab for treating giant cell arteritis
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
- NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
- NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
- NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
- NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
- NICE TA685: Anakinra for treating Still’s disease
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
- NICE TA718: Ixekizumab for treating axial spondyloarthritis
- NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
- NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis
- NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
- NICE TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
- NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
- NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA829: Upadacitinib for treating active ankylosing spondylitis
- NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
- NICE TA916: Bimekizumab for treating active psoriatic arthritis
- NICE TA918: Bimekizumab for treating axial spondyloarthritis
- NICE TA920: Tofacitinib for treating active ankylosing spondylitis
- NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)
- North Cumbria Shared Care Guidelines
- NTAG - Treatment Appraisal Decision Summary - Rituximab Biosimilars
- NTAG: Transanal irrigation (TAI) systems (Peristeen Plus®, Aquaflush®, and QuFora®) for neurogenic bowel dysfunction, chronic constipation and chronic faecal incontinence
- South Tyneside & Sunderland APC Shared Care Guideline - Methotrexate in Rheumatology
- South Tyneside & Sunderland APC Shared Care Guidelines
- Tees Shared Care Guidance
- Tees Valley Shared Care Guideline: Ciclosporin
- Tees Valley Shared Care Guideline: Methotrexate